



## STARPHARMA'S US ASSOCIATE DNT RECEIVES "TECHNOLOGY INNOVATION OF THE YEAR" AWARD

Melbourne, Australia – 10 November 2005 – Dendritic Nanotechnologies, Inc (DNT), an investee company of Starpharma Holdings Limited, has released the attached press announcement regarding the "Advanced Medical Applications of the Year" Award by Frost & Sullivan for its work in developing and commercializing the Priostar™ family of dendrimers.

---

### About Starpharma:

Starpharma Holdings Limited (ASX:SPL, USOTC:SPHRY) leads the world in the application of nanotechnology to pharmaceuticals. The Company's lead development product is VivaGel™, a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.

VivaGel™ is the first example of a product to come from Starpharma's dendrimer-based discovery pipeline, which also includes specific programs in the fields of ADME Engineering™ (using dendrimers to control where and when drugs go when introduced to the body), Polyvalency (using the fact that dendrimers can activate multiple receptors simultaneously) and Targeted Diagnostics (using dendrimers as a scaffold to which both location-signaling and targeting groups are added to allow location of specific cell type, such as cancer cells).

Starpharma also has equity interests in two companies:

- *Dendritic NanoTechnologies, Inc. (DNT)* – established with the pioneer of dendrimer nanotechnology Dr Donald A. Tomalia and based in Michigan, USA; and
- *Dimerix Bioscience Pty Ltd* – a specialist drug development company established to commercialise unique technology developed at the Western Australian Institute for Medical Research in the new field of receptor coupling, specifically G-Protein coupled receptors ("GPCRs").

**Dendrimers:** A type of precisely-defined, branched nanoparticle. Dendrimers have applications in the medical, electronics, chemicals and materials industries.

**Microbicides:** A microbicide inactivates, kills or destroys microbes such as viruses and bacteria. Microbicides may be formulated as gels, creams, sponges, suppositories or films with the purpose of reducing significantly the incidence of STIs. They are intended for vaginal or rectal use to afford protection for varying periods, from several hours up to days. Microbicides may also be designed to have a contraceptive function.

**American Depositary Receipts (ADRs):** Starpharma's ADRs trade under the code **SPHRY** (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Stock Exchange. The Bank of New York is the depositary bank.

### For further information:

Media	Starpharma <a href="http://www.starpharma.com">www.starpharma.com</a>	
<b>Rebecca Wilson</b> Buchan Tel: +61 2 9237 2800 Mob: +61 417 382 391 <a href="mailto:rwilson@bcg.com.au">rwilson@bcg.com.au</a>	<b>Dr John Raff</b>  Chief Executive Officer +61 3 8532 2701 <a href="mailto:john.raff@starpharma.com">john.raff@starpharma.com</a>	<b>Ben Rogers</b>  Company Secretary +61 3 8532 2702 <a href="mailto:ben.rogers@starpharma.com">ben.rogers@starpharma.com</a>



## FOR IMMEDIATE RELEASE

### **Dendritic Nanotechnologies' Priostar Family of Dendrimers Receives "Technology Innovation of the Year" Award**

**MOUNT PLEASANT, MI—November 9, 2005—**Dendritic Nanotechnologies Inc. (DNT), a company focused on the discovery, development, and commercialization of dendrimer technologies to create a new generation of innovative products for the identification and treatment of human diseases, has been awarded the "Advanced Medical Applications Technology Innovation of the Year" Award by a leading global growth consulting company. The Award was bestowed on DNT by Frost & Sullivan for its work in developing and commercializing the Priostar™ family of dendrimers.

Frost & Sullivan selected DNT from a field of several dozen nanotech companies. After a selection process that included primary participant interviews and extensive primary and secondary research, Frost & Sullivan concluded that DNT's dendrimer-based nanostructures "represent a potent delivery platform for a vast array of diagnostics and therapeutics and could be employed to manufacture a variety of biotechnology and pharmaceutical products."

Of particular importance during the evaluation process was the precise control over size, composition, surface functionality and interior space offered by the Priostar family of dendrimers. Precise control of their physical characteristics means that Priostar dendrimers can be tailored to a wide array of markets, including medical and health, food and agriculture, energy and electronics, environmental and industrial safety, personal and household, and chemicals and manufacturing.

Frost & Sullivan also noted that: "While nanotechnology in general has promised great advances, there are relatively few tangible products with clear and present applications. Moreover, many of these products cannot be cost-effectively produced in large enough volumes. DNT's dendritic nanostructures appear to be an exception. These dendritic polymers can serve as effective delivery vehicles *in vitro* and *in vivo* due to their specific, precise and predictable architecture."

"DNT's Priostar dendrimers, as nanoscale building blocks, radically change the current economics of nanotechnology and we are pleased to see them validated by a prestigious growth consulting company such as Frost & Sullivan," said Robert Berry, DNT's chief executive officer. "Priostar has established a new price point for an essential technology, placing it within reach of new applications and uses."

#### **About Frost & Sullivan**

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit [www.frost.com](http://www.frost.com).

**About DNT**

Dendritic Nanotechnologies Inc. (DNT) is focused on the discovery, development, and commercialization of dendrimer technologies to create a new generation of innovative products for the identification and treatment of human diseases. DNT's proprietary dendrimer platform serves as a targeted diagnostic and therapeutic delivery system for a wide variety of drugs to cancer cells and other diseases. Improved efficacy, enhanced solubility, and lower toxicity have been demonstrated for many existing drugs. DNT is committed to producing commercially viable dendrimers that can be manufactured in large quantities, and to driving down manufacturing complexity and costs. The company has a patent pending on its Priostar™ family of dendrimers, a novel dendrimer family that breaks through previous cost and manufacturing barriers.

DNT's technology development is directed by Donald A. Tomalia, Ph.D., president and chief technical officer. Dr. Tomalia is the inventor of dendrimers and has led numerous commercial developments during a 25-year management and senior scientist career with The Dow Chemical Company. See [www.dnanotech.com](http://www.dnanotech.com).

Starpharma (ASX:SPL; USOTC: SPHRY) is an equity holder in DNT and is focused on the development and application of dendrimer nanotechnologies as drugs against major diseases. Starpharma's lead dendrimer product, VivaGel™ is currently in expanded human safety clinical trials under an active IND with the US FDA. VivaGel™ is a topical microbicide gel product that is being developed for women as a preventative against the sexual transmission of HIV and other sexually transmitted infections.

STARBURST and Priostar are trademarks of Dendritic Nanotechnologies Inc. All other trademarks mentioned herein are held by their respective owners.

**Media contact:**

Tim Cox — Zing Public Relations  
+1-650-369-7784 office — +1-650-888-6116 cell  
[tim@zingpr.com](mailto:tim@zingpr.com)